Click here to see if you may qualify
Upon initial eligibility, a patient outreach representative will call you and help guide you through additional eligibility questions
The team at a participating study center will determine if you are eligible to participate in the study and what would be required for participation
Throughout the study, you will take the investigative treatment daily and have a mix of virtual and in person visits, depending on your needs. You will be asked to keep a diary to record specific experiences and answer questions about your experience living with UC
Click here and enter your information to express interest in the study.
A “flare” or “active symptoms” usually consist of issues like frequent or urgent bowel movements, diarrhea, bloody stools, and/or abdominal pain. You may also experience fatigue, lack of appetite and weight loss.
You can still fill out the questionnaire at this time. We’ll save your information and send you reminders to check if you may pre-qualify at a later date. Alternatively, you can return to this website when you are experiencing symptoms (a flare) to see if you then pre-qualify.
The drug will be taken orally (by mouth) once per day.
You’re free to withdraw from the study at any time. If you sign up, your participation is completely voluntary.
There is no cost to either you or your insurance provider for participation in this trial. You may be reimbursed for your travel expenses.
No, health insurance is not required to participate in the Arena IBD studies.
Etrasimod has been tested in small numbers of healthy volunteers and in people with medical conditions, including UC.
Research studies are rigorously designed to test the investigational drug for safety and effectiveness. One or more of your answers have placed you outside of the strict guidelines for this trial. That does not mean, however, that you will not qualify for different research studies either now or in the future.
The aim of current treatments is to reduce the signs and symptoms of UC. The available treatments may improve symptoms for some people, but they may have unacceptable side effects, be difficult to stick to, or not work well for others. Therefore, there is a need to develop and find new treatments for people with UC through clinical studies.
Arena Pharmaceuticals was founded in 1997 and now operates from three locations – San Diego, California and Boston, Massachusetts in the US and Zug, Switzerland.
It is their mission to improve the lives of those suffering from IBD around the world. They know that living with IBD isn’t always easy and this drives their commitment to discover new treatments and help them to become available to patients.